This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. Announcements
  3. Selected Announcement

Data presented at American College of Rheumatology (ACR) 2020

Due to COVID-19 concerns, many medical congresses are being presented virtually. Virtual congress materials from ACR can be accessed at https://www.rheumatology.org/

 

TREMFYA PsA

DISCOVER-1: TNF-experience vs naïve subgroups
DISCOVER-2: Collagen turnover Biomarkers
DISCOVER-1&-2: WK-24 Comp indices
DISCOVER-1&-2: Subgroups by BL Characteristics
DISCOVER 1&2: WK-52 Spondylitis
DISCOVER-1&-2: WK-52 Integrated safety
DISCOVER-1&-2: WK-52 FACIT-Fatigue
GUS PSA Network Meta-Analysis
DISCOVER-2 Week 52 S/S/x-ray*
DISCOVER-1&-2 Week24 Enthesitis/Dactylitis*
DISCOVER-2 24-wk- Work Productivity*
DISCOVER-1 Week 52 S/S*
DISCOVER-1 PROMIS-29 validation/Reliability*
DISCOVER-1& -2 Sustained serum biomarker reduction
Modified DISCOVER 2/DLQI (EADV)*
VOYAGE-1&-2 PsA 4yr PsA subgroup*

 

PsA Real World Evidence

Impact of Fatigue in PsA
Impact of Improving Deteriorating in PsA
Flares in PsA
Impact of Depression in PsA*
Skin involvement in PsA*
Pso PsA Market Scan: Cost of Illness*
Pso PsA Market Scan: Work Disability*
Axial PsA clinical characteristics by HLA-B27 status

 

SIMPONI ARIA

AWARE: 52 Wk PROMIS SA vs Rem
AWARE: 52 Wk Comparative effectiveness of GLM-IV vs Dose escalated IFX*

 

STELARA/MA SLE

UST SLE 2001: 2-yr data 
UST SLE 2001: Biomarkers
ANTI IFN-I (CNTO6358/JNJ-55920839):  Biomarkers
Predictors of SLE diagnosis
Remission, LLDAS, flares
Impact of Remission and LDA on HCRU
Impact of high DA on HCRU, QoL & Productivity*
Impact of flares on HCRU QoL and Productivity*

 

STELARA PsA

PsABIO: Age groups and efficacy

 

*ENCORE